NCT04925973进行中（未招募）2 期
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (the TRIUMPH Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Clinical response at day 7
研究概览
简要总结
The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults ages 18 to 75 with ulcerative colitis (either known UC based on prior history with histological confirmation or new diagnosis)
- •Symptoms consistent with severe acute ulcerative colitis as defined by modified Truelove and Witts score (MTWSI) > 10 points
- •Primary non-response or secondary loss of response to anti-TNFα/anti-integrin therapies/anti-interleukin therapies OR immunomodulators OR non-response to minimum 3 days and maximum of 7 days of intravenous corticosteroids (intravenous at dose equivalent of prednisone 50mg daily / methylprednisolone 40mg daily).
- •a. For patients using anti-TNFα or anti-integrin or anti-interleukin therapies, they must have been on a stable dose of one of the following: i. Adalimumab in the 14 days prior to screening ii. Golimumab in the 28 days prior to screening iii. Infliximab in the 28 days prior to screening iv. Vedolizumab in the 28 days prior to screening v. Ustekinumab in the 28 days prior to screening b. Persons on biologic therapy will have drug levels drawn during the time of hospitalization
- •Able to provide written informed consent
- •Treatment with concomitant corticosteroids or 5-ASA products is permitted, however patients will be placed on a corticosteroid weaning regimen after initiating study protocols. For patients using biologics or immunomodulators, these will be discontinued prior to initiation of tofacitinib.
排除标准
- •Enteric infection confirmed before inclusion into study by stool microscopy, culture, or histology (including Clostridum difficile, Campylobacter, Salmonella, Shigella, Cytomegalovirus, Human Immunodeficiency Virus, Epstein Bar Virus)
- •Clinical signs of sepsis
- •Patient has indication for surgery instead of medical rescue therapy (ex. toxic megacolon, massive exsanguination, or perforation)
- •Positive blood (beta-HCG) pregnancy test or currently lactating, or women of childbearing potential not willing to use double barrier contraception for the duration of the active part of the study and for 4 weeks after the last dose of tofacitinib
- •a. Participants will be sufficiently educated to ensure compliance with double barrier contraception prior to enrollment in the study
- •Current malignancy
- •Serious co-morbidity including but not limited to:
- •a. Immunodeficiency b. Recent myocardial infarction or stroke (in the past month) c. History of heart, respiratory, renal, or hepatic failure i. Heart failure as defined as ejection fraction of <50% as determined by transthoracic echo ii. Respiratory failure as defined as PaO2 <60mmHg iii. Hepatic failure as defined as INR > 2.5 with total bilirubin >30 iv. Renal failure as defined as a creatinine clearance of 40ml/min (as estimated by the Cockroft-Gault equation) d. Infections such as abscess, opportunistic infection, or sepsis
- •English not adequate in absence of local translation service
- •Currently taking part in another clinical trial
- •Treatment with tofacitinib in the 3 months prior to screening
- •Use of strong CYP (3A4 or 2C19) inhibitors or inducers such as antifungals (ketoconazole, fluconazole), St John's wort or rifampin a. Patients will be told to avoid consumption of grapefruit juice
研究组 & 干预措施
Treatment arm
Experimental
Tofacitinib 10mg PO BID
干预措施: Tofacitinib 10 MG [Xeljanz] (Drug)
结局指标
主要结局
Clinical response at day 7
时间窗: 7 days
To determine the effectiveness (combined and endoscopic response) and safety of tofacitinib in patients with acute severe UC who experience treatment failure to steroids or anti-TNFα/anti-integrin therapies/anti-interleukin therapies. The primary outcome of this study is to assess clinical response at day 7 among patients who receive tofacitinib. This will be determined by the percentage of patients who achieve clinical response at day 7 (MTWSI reduction 3 or more points and MTWSI \< 10).
次要结局
- 1. Percentage of patients who achieve clinical remission at day 7, and weeks 12, 26, and 52 (Partial Mayo score < 2, with no subscore >1)(52 weeks)
- Number of colectomies (emergency and planned) during the 52 weeks(52 weeks)
- Number of patients requiring switch in therapy (i.e. initiation of another biological medication, start of a different clinical trial with another active drug, etc) during the 52 weeks(52 weeks)
- Percentage of patients who achieve clinical response at weeks 12, 26, and 52 (MTWSI reduction 3 or more points and MTWSI < 10)(52 weeks)
- For patients who have response, to determine the mean number of days before detection of clinically significant response (MTWSI reduction of 3 or more points) population.(7 days)
- To determine the rate of corticosteroid-free clinical remission based on Number of patients with initial Mayo 2/3 disease at flexible sigmoidoscopy that achieve endoscopic improvement (Mayo score 0 or 1) at week 26(Week 26)
- Comparison of absolute change from baseline endoscopic Mayo score at week 26(Week 26)
- Comparison of number of patients with severe colitis based on histology who are able to achieve histological improvement (mild or inactive colitis) at week 26(Week 26)
- Proportion of individuals who experience a severe adverse event over the course of treatment(52 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisSarcoidosis, PulmonarySarcoidosis LungSarcoidosisNCT03793439Oregon Health and Science University5
已完成
4 期
effectiveness of tofacitinib in moderate to severe ulcerative colitis compared to steroidCTRI/2023/09/057448Shankar Roy94
已完成
3 期
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)Ankylosing SpondylitisNCT03502616Pfizer270
已完成
4 期
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia AreataAlopecia AreataNCT03800979Institute of Dermatology, Thailand19
Unknown
2 期
Tofacitinib Combined With Chidamide in R/R ENKTCLExtranodal NK/T-cell LymphomaNCT03598959Sichuan University20